Loading...
•
Dec 31, 2021
Replimune Q3 2022 Earnings Report
Replimune announced financial results for the third fiscal quarter ended December 31, 2021 and provided a business update.
Key Takeaways
Replimune Group Inc. reported financial results for the fiscal third quarter ended December 31, 2021, and provided a business update, highlighting upcoming milestones and data presentations.
Investor event planned to present commercial strategy and RP2/3 development plans.
Plans to establish a broad, high-value skin cancer franchise with RP1.
Overview of mid-stage development plans for RP2/3.
Release of data from registrational studies expected to highlight the platform’s potential.
Forward Guidance
Replimune believes that existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...